We are studying a new treatment combination for patients with untreated or relapsed high-risk mantle-cell lymphoma. The trial aims to see if this combination works better than Venetoclax alone.
We are studying a combination of chemotherapy and Lorlatinib for patients with ALK positive NSCLC who have had disease progression outside the brain. The goal is to see if this treatment improves outcomes compared to past therapies.
We are studying a new treatment combining [177Lu]Lu-NeoB and capecitabine for adults with specific metastatic breast cancer. The goal is to find the best doses and evaluate how well it works after other treatments have failed.
We are exploring a new drug for patients with newly diagnosed glioblastoma alongside standard care, and for those with recurrent glioblastoma as a single treatment. The goal is to find the best dose for effective treatment.
We are studying whether on-demand Anakinra can help patients with colchicine-resistant FMF manage painful attacks without daily therapy. This trial compares its effectiveness to standard pain management options.
We are studying a combination of chemotherapy and immunotherapy for patients with locoregionally advanced penile cancer. The goal is to see if this treatment can effectively shrink tumors before surgery and to assess its safety.
We are testing a new treatment called BMN 351 to see if it is safe and well-tolerated in people with Duchenne Muscular Dystrophy. The study will also look at how the drug is processed in the body.
We are studying a new treatment combination for patients with advanced gastric cancer to see if it improves response rates and safety. This trial focuses on those with a specific biomarker to better understand treatment effectiveness.
We are testing a new drug, AZD3470, for patients with advanced solid tumors lacking the MTAP gene. The study aims to evaluate its safety and effectiveness, both alone and with other cancer treatments.
We are studying a new treatment for people with non-small cell lung cancer who have specific mutations. The goal is to see if it can improve their condition compared to standard therapies.
We are studying the safety and effectiveness of a new treatment combining RO7204239 with risdiplam for individuals with spinal muscular atrophy. This trial will help us understand how well this combination works compared to a placebo.
We are testing the effectiveness of TAK-279 for people with moderately to severely active ulcerative colitis. The study aims to see if it helps achieve remission and improves symptoms compared to a placebo.
We are testing a new treatment called selpercatinib for patients with RET fusion-positive non-small cell lung cancer. The goal is to see if it improves outcomes compared to a placebo.
We are evaluating the long-term safety of treatments for pulmonary hypertension in participants who have previously received these interventions. This study aims to ensure ongoing safety for those already involved in related research.
We are investigating whether dimethyl fumarate can improve symptoms in patients with adrenomyeloneuropathy compared to a placebo. The trial also looks at the safety of this medication.
We are studying whether intranasal fentanyl or ketamine is more effective than oral morphine for reducing pain in children with limb injuries. This trial involves children aged 2 to 17 in emergency departments.
We are offering ongoing access to the medication latozinemab for individuals with neurodegenerative diseases who have participated in earlier studies. The trial will monitor safety and any clinical benefits from continued treatment.
We are studying whether adding LSTA1 to standard treatment (temozolomide) improves survival for patients with newly diagnosed GBM compared to a placebo. The trial also looks at quality of life and other important health measures.
We are studying whether intermittent hormone therapy can maintain effectiveness and improve daily life for men with advanced prostate cancer. This trial compares it to continuous hormone therapy to see which is better for patients.
We are testing a new drug, CP-506, in patients with specific solid tumors to see how safe it is and how well it works. This study may help those with tumors that have certain genetic features or who are not responding well to current treatments.